Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: UnivDatos Market Insights Pvt Ltd | PRODUCT CODE: 1081029

Cover Image

PUBLISHER: UnivDatos Market Insights Pvt Ltd | PRODUCT CODE: 1081029

CAR T-Cell Therapy Market: Current Analysis and Forecast (2021-2027)

PUBLISHED:
PAGES: 229 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 3999
PDF (Site License)
USD 5099
PDF (Global License)
USD 7577

Add to Cart

The global CAR T-cell therapy Market is anticipated to grow with an exponential CAGR over the forecast period (2021-2027). CAR T-Cell Therapy is a type of immunotherapy that is regarded as s revolutionary therapy for cancer. In this therapy, the T-cells are taken from the patient's blood and are modified in the laboratory for attacking the cancer cells. CAR T-cell therapy is most commonly used to treat certain blood cancers and is being studied for the treatment of other cancer types.

The growing adoption of CAR T-Cell Therapy can be attributed to the surging incidences of cancer coupled with a rapidly growing geriatric population. According to the United Nations, the 60+ aged population was 962 million in 2017 which is more than twice that it was in 1980 at 382 million. The number of elderly is expected to double again by 2050 and reach nearly 2.1 billion worldwide. Further, it has been estimated by CDC that the number of cancer cases in the US will increase 49% each year, from 1,534,500 in 2015 to 2,286,300 in 2050, with the largest percentage increase among adults aged ≥75 years. This exponential increase in cancer prevalence globally has created a buzz among various pharmaceutical companies for investing in the development of novel and effective cancer treatment. Thereby, boosting the growth of the CAR T-Cell Therapy Market.

Furthermore, the CAR T-Cell Therapy market is anticipated to grow on account of the growing technological advancement, a large number of ongoing research activities in this field, rising government and public-private investments, a huge CAR T-cell pipeline, and increasing FDA approvals. For example, in February 2022, the FDA approved carvykti, a new customized, cell-based treatment from Johnson & Johnson, for the treatment of multiple myeloma. However, some of the restraints in the market including high-touch commercial models and side-effects associated with CAR T-cell therapy are impeding the growth of this market all over the world.

Novartis AG, Gilead Sciences, Inc., Amgen, Inc., Juno Therapeutics, Eli Lilly and Company, Sorrento Therapeutics, Fate Therapeutics, Inc., Johnson & Johnson, Celgene Corporation, Bluebird bio, Inc., are some of the prominent players operating in the CAR T-cell therapy market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with CAR T-cell therapy.

Insights Presented in the Report

"Amongst Product, yescarta segment holds the major share"

Based on product, the CAR T-Cell Therapy market is segmented into abecma, breyanzi, Kymriah, tecartus, and yescarta. The yescarta segment accounted for a significant market share in 2020 and it is estimated that it will grow rapidly during the projected timeframe. Yescarta is the first CAR T-cell therapy that has been approved for certain types of non-Hodgkin lymphoma (NHL). The growth of this segment can be attributed to the customization of each dose of yescarta as the treatment is created by using a patient's immune system to help fight the lymphoma.

"Amongst Indication, relapsed Large B-cell Lymphoma segment holds the major share"

Based on indication, the CAR T-Cell Therapy market is divided into relapsed Large B-cell Lymphoma, Acute Lymphoblastic Leukemia (ALL), and Multiple Myeloma. The relapsed Large B-cell Lymphoma segment occupied the major share of the CAR T-Cell Therapy market in 2020 and it is expected to grow with a substantial CAGR in the upcoming years. The growth of this segment is attributed to the growing incidences of relapsed large b-cell lymphoma and the increase in FDA approval of CAR T-cell therapy for the same.

"Amongst End-Users, hospitals segment holds the major share"

Based on end-users, the market is fragmented into hospitals, cancer treatments centers, and others. In 2020, hospitals segment grabbed a considerable market share, and it is expected to grow at a significant CAGR during the forecast period owing to the increasing number of hospitals in various emerging economies, better infrastructure & accessibility of various healthcare services at hospitals leading to the growing preference of patients for treatment in the hospital settings. However, cancer treatments centers are also likely to witness the fastest growth during the forecast period.

"North America represents one of the largest markets of CAR T-cell therapy market"

For a better understanding of the market dynamics of the CAR T-cell therapy market, a detailed analysis was conducted for different regions across the globe including North America (the U.S, Canada, and the Rest of North America), Europe (Germany, France, Spain, United Kingdom, Italy, and Rest of Europe), Asia-Pacific (China, India, Australia, Japan, and Rest of APAC), Rest of World has been conducted. North America constitutes a major market for the CAR T-cell therapy market industry and generated revenue of USD XX Million in 2020 owing to strong healthcare infrastructure and growing adoption of CAR T-cell therapy in the region.

Reasons to buy this report:

The study includes market sizing and forecasting analysis validated by authenticated key industry experts

The report presents a quick review of overall industry performance at one glance

The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments

Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry

The study comprehensively covers the market across different segments

Deep dive regional level analysis of the industry

Customization Options:

The global CAR T-cell therapy market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

Product Code: UMHE21771

TABLE OF CONTENTS

1 MARKET INTRODUCTION

  • 1.1 Market Definitions
  • 1.2 Objective of the Study
  • 1.3 Limitation
  • 1.4 Stake Holders
  • 1.5 Currency Used in Report
  • 1.6 Scope of the Global CAR T-Cell Therapy Study

2 RESEARCH METHODOLOGY OR ASSUMPTION

  • 2.1 Research Methodology for the Global CAR T-Cell Therapy Market
    • 2.1.1 Main Objective of the Global CAR T-Cell Therapy Market

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 COVID-19 IMPACT

6 GLOBAL CAR T-CELL THERAPY MARKET REVENUE

7 MARKET INSIGHTS BY PRODUCT

  • 7.1 Abecma
  • 7.2 Breyanzi
  • 7.3 Kymriah
  • 7.4 Tecartus
  • 7.5 Yescarta

8 MARKET INSIGHTS BY INDICATION

  • 8.1 Relapsed Large B-cell Lymphoma
  • 8.2 Acute Lymphoblastic Leukemia (ALL)
  • 8.3 Multiple Myeloma

9 MARKET INSIGHTS BY END-USERS

  • 9.1 Hospitals
  • 9.2 Cancer Treatments Centers
  • 9.3 Others

10 MARKET INSIGHTS BY REGION

  • 10.1 NORTH AMERICA CAR T-CELL THERAPY MARKET
    • 10.1.1 United States
    • 10.1.2 Canada
    • 10.1.3 Rest of North America
  • 10.2 EUROPE CAR T-CELL THERAPY MARKET
    • 10.2.1 Germany
    • 10.2.2 France
    • 10.2.3 United Kingdom
    • 10.2.4 Spain
    • 10.2.5 Italy
    • 10.2.6 Rest of Europe
  • 10.3 ASIA PACIFIC CAR T-CELL THERAPY MARKET
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 Australia
    • 10.3.5 Rest of Asia Pacific
  • 10.4 REST OF THE WORLD CAR T-CELL THERAPY MARKET

11 CAR T-CELL THERAPY MARKET DYNAMICS

  • 11.1 Market Drivers
  • 11.2 Market Challenges
  • 11.3 Impact Analysis

12 CAR T-CELL THERAPY MARKET OPPORTUNITIES

13 CAR T-CELL THERAPY MARKET TRENDS & INSIGHTS

14 LEGAL & REGULATORY FRAMEWORK

15 DEMAND AND SUPPLY SIDE ANALYSIS

  • 15.1 Demand Side Analysis
  • 15.2 Supply Side Analysis
    • 15.2.1 Top Product Launches
    • 15.2.2 Top Business Partnerships
    • 15.2.3 Top Merger & Acquisitions

16 VALUE CHAIN ANALYSIS

17 COMPETITIVE SCENARIO

  • 17.1 Porter's Five forces analysis
    • 17.1.1 Bargaining power of Supplier
    • 17.1.2 Bargaining power of Buyer
    • 17.1.3 Industry Rivalry
    • 17.1.4 Availability of Substitute
    • 17.1.5 Threat of new Entrants
  • 17.2 Competitive Landscape
    • 17.2.1 Company Shares, By Revenue

18 COMPANY PROFILED

  • 18.1 Novartis AG
  • 18.2 Gilead Sciences, Inc.
  • 18.3 Amgen, Inc.
  • 18.4 Juno Therapeutics
  • 18.5 Eli Lilly and Company
  • 18.6 Sorrento Therapeutics
  • 18.7 Fate Therapeutics, Inc.
  • 18.8 Johnson & Johnson
  • 18.9 Celgene Corporation
  • 18.10 Bluebird bio, Inc.

19 DISCLAIMER

Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!